A new human-based study called SMILEE as a Phase IIA clinical trial of a new Viaskin product from DBV Technologies has begun. The first enrollment of the study, which targets children aged 4-17, is looking at the efficacy of the Viaskin Milk patch.
The study is specifically looking at whether the new patch, which has been under development for some time alongside the company’s peanut allergy patch, can deliver safe skin-patch-based immunotherapy to build tolerance in those allergic to milk or milk products.
Specifically, the study is targeting those children who have an eosinophilic esophagitis (EoE) reaction to milk.
EoE affects one in every 2,000 children and is a serious condition.
EoE is not a milk intolerance, but a potentially life-threatening reaction with symptoms that can include vomiting, abdominal pain, and swelling of the esophagus.
The Viaskin Milk patch is a potential new therapy for EoE induced by milk allergies. The study for the patch is being centered at the Children’s Hospital of Philadelphia under the direction of Dr. Jonathan Spergel.